Data Sheet (Cat.No.T37085)

TargetMol®
A DRUG SCREENING EXPERT

Luxeptinib

Chemical Properties

CAS No. : 1616428-23-9

Formula: C25H17F4N5O2

Molecular Weight: 495.43

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	Luxeptinib (CG-806) is a novel pan-FLT3/pan-BTK inhibitor that is administered orally. It exhibits potent and reversible inhibition of these enzymes, acting through a non-covalent mechanism. Luxeptinib effectively induces cell cycle arrest, apoptosis, or autophagy in acute myeloid leukemia cells [1][2][3][4].
In vitro	Luxeptinib (MEC-1 CLL cells; 0.1~10 μM; 72 hours) inhibits cells proliferation with an IC50 of 32 nM[1].Luxeptinib inhibits BCR signaling-induced phosphorylation of BTK, PLCg2, AKT, ERK1/2, S6 ribosomal protein and strongly suppresses SYK phosphorylation in primary chronic lymphocytic leukemia (CLL) cells[1]. Luxeptinib (MV4-11 cells; 500 pM; 1 hour) completely inhibits phosphorylation of FLT3 and STAT5[2].

Solubility Information

Solubility	DMSO: 125 mg/mL (252.31 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0184 mL	10.0922 mL	20.1845 mL
5 mM	0.4037 mL	2.0184 mL	4.0369 mL
10 mM	0.2018 mL	1.0092 mL	2.0184 mL
50 mM	0.0404 mL	0.2018 mL	0.4037 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Ekaterina Kim MS, et al. CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells. bloodjournal Blood blood (2019). 134 (Supplement_1) : 3051.

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481